I founded PeptidesDNA to answer a question the peptide world mostly ignores: your genetics change how you respond to a given peptide. I build the scoring engine that maps a person's DNA to the peptides most likely to work for them, and I write and research the reference content that explains the why behind it.
I'm also the founder of GLP-1 Price Tracker, where I track telehealth pricing and FDA enforcement actions. GLP-1 medications — semaglutide, tirzepatide — are peptides, so both projects run on the same lens: verified data and peer-reviewed evidence over marketing claims.
What Julian can speak to
Written for journalists and researchers deciding whether to get in touch. Each of these is work done here, on the record, with the sources cited on the page.
- How consumer DNA data is actually used to rank compounds, and where that reaches its limits
- Why most peptide marketing claims outrun the evidence, and how to read a study behind one
- What the peptide market looks like from the inside: what people buy, what it costs, what is unregulated
- How an evidence-graded corpus is built and kept honest when the underlying research is mostly animal work
Press and research enquiries: hello@peptidesdna.com
How PeptidesDNA writes and reviews its content, and who is accountable for it, is set out on the editorial team page.